[1] To KK-W, Sridhar S, Chiu KH-Y, Hung DL-L, Li X, Hung IF-N, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect 2021;10:507–35. https://doi.org/10.1080/22221751.2021.1898291.
[2] COVID - Coronavirus Statistics - Worldometer n.d. https://www.worldometers.info/coronavirus/ (accessed March 13, 2023).
[3] Khan RU, Almakdi S, Alshehri M, Kumar R, Ali I, Hussain SM, et al. Probabilistic Approach to COVID-19 Data Analysis and Forecasting Future Outbreaks Using a Multi-Layer Perceptron Neural Network. Diagnostics 2022;12:2539. https://doi.org/10.3390/diagnostics12102539.
[4] Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 2021;22:757–73. https://doi.org/10.1038/s41576-021-00408-x.
[5] Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 2022;23:3–20. https://doi.org/10.1038/s41580-021-00418-x.
[6] Beheshtirouy S, Khani E, Khiali S, Entezari-Maleki T. Investigational antiviral drugs for the treatment of COVID-19 patients. Arch Virol 2022;167:751–805. https://doi.org/10.1007/s00705-022-05368-z.
[7] Kim S. COVID-19 Drug Development 2022;32:1–5. https://doi.org/10.4014/jmb.2110.10029.
[8] Commissioner O of the. Know Your Treatment Options for COVID-19. FDA 2023.
[9] Research C for DE and. Coronavirus (COVID-19) | Drugs. FDA 2023. https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs (accessed March 13, 2023).
[10] Veklury Side Effects: Common, Severe, Long Term. DrugsCom n.d. https://www.drugs.com/sfx/veklury-side-effects.html (accessed September 18, 2023).
[11] Olumiant Side Effects: Common, Severe, Long Term. DrugsCom n.d. https://www.drugs.com/sfx/olumiant-side-effects.html (accessed September 18, 2023).
[12] Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol 2021;19:685–700. https://doi.org/10.1038/s41579-021-00630-8.
[13] Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA. An Updated Review on SARS-CoV-2 Main Proteinase (MPro): Protein Structure and Small-Molecule Inhibitors. Curr Top Med Chem n.d.;21:442–60.
[14] Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 2020;30:127377. https://doi.org/10.1016/j.bmcl.2020.127377.
[15] Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn 2021;39:3409–18. https://doi.org/10.1080/07391102.2020.1758788.
[16] Arya R, Kumari S, Pandey B, Mistry H, Bihani SC, Das A, et al. Structural insights into SARS-CoV-2 proteins. J Mol Biol 2021;433:166725. https://doi.org/10.1016/j.jmb.2020.11.024.
[17] Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, et al. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants – Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) – a molecular docking study. J Biomol Struct Dyn 2022;40:190–203. https://doi.org/10.1080/07391102.2020.1810778.
[18] Bepari AK, Reza HM. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation. PeerJ 2021;9:e11261. https://doi.org/10.7717/peerj.11261.
[19] Roy R, Sk MF, Jonniya NA, Poddar S, Kar P. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies. J Biomol Struct Dyn 2022;40:6556–68. https://doi.org/10.1080/07391102.2021.1897680.
[20] Gupta Y, Kumar S, Zak SE, Jones KA, Upadhyay C, Sharma N, et al. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Bioorg Med Chem 2021;47:116393. https://doi.org/10.1016/j.bmc.2021.116393.
[21] Khan A, Ali SS, Khan MT, Saleem S, Ali A, Suleman M, et al. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro). J Biomol Struct Dyn 2020:1–12. https://doi.org/10.1080/07391102.2020.1779128.
[22] Gimeno A, Ojeda-Montes MJ, Tomás-Hernández S, Cereto-Massagué A, Beltrán-Debón R, Mulero M, et al. The Light and Dark Sides of Virtual Screening: What Is There to Know? Int J Mol Sci 2019;20:1375. https://doi.org/10.3390/ijms20061375.
[23] Cheng T, Li Q, Zhou Z, Wang Y, Bryant SH. Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review. AAPS J 2012;14:133–41. https://doi.org/10.1208/s12248-012-9322-0.
[24] Chilingaryan G, Abelyan N, Sargsyan A, Nazaryan K, Serobian A, Zakaryan H. Combination of consensus and ensemble docking strategies for the discovery of human dihydroorotate dehydrogenase inhibitors. Sci Rep 2021;11:11417. https://doi.org/10.1038/s41598-021-91069-7.
[25] Mysinger MM, Carchia M, Irwin JohnJ, Shoichet BK. Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking. J Med Chem 2012;55:6582–94. https://doi.org/10.1021/jm300687e.
[26] https://pharmit.csb.pitt.edu/ n.d.
[27] Sunseri J, Koes DR. Pharmit: interactive exploration of chemical space. Nucleic Acids Res 2016;44:W442–8. https://doi.org/10.1093/nar/gkw287.
[28] https://www.rcsb.org/ n.d.
[29] Li J, Lin C, Zhou X, Zhong F, Zeng P, Yang Y, et al. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332. J Virol 2022;96:e02013-21. https://doi.org/10.1128/jvi.02013-21.
[30] Yang KS, Leeuwon SZ, Xu S, Liu WR. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. J Med Chem 2022;65:8686–98. https://doi.org/10.1021/acs.jmedchem.2c00404.
[31] Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 2021;374:1586–93. https://doi.org/10.1126/science.abl4784.
[32] Dampalla CS, Rathnayake AD, Galasiti Kankanamalage AC, Kim Y, Perera KD, Nguyen HN, et al. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease. J Med Chem 2022;65:7818–32. https://doi.org/10.1021/acs.jmedchem.2c00224.
[33] Su H, Yao S, Zhao W, Zhang Y, Liu J, Shao Q, et al. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat Commun 2021;12:3623. https://doi.org/10.1038/s41467-021-23751-3.
[34] Chen Y, Yang W-H, Chen H-F, Huang L-M, Gao J-Y, Lin C-W, et al. Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2. J Biol Chem 2022;298. https://doi.org/10.1016/j.jbc.2022.101658.
[35] Douangamath A, Fearon D, Gehrtz P, Krojer T, Lukacik P, Owen CD, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun 2020;11:5047. https://doi.org/10.1038/s41467-020-18709-w.
[36] Abagyan R, Totrov M, Kuznetsov D. ICM—A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Comput Chem 1994;15:488–506. https://doi.org/10.1002/jcc.540150503.
[37] Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010;31:455–61. https://doi.org/10.1002/jcc.21334.
[38] Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91. https://doi.org/10.1002/jcc.21256.
[39] Poli G, Granchi C, Rizzolio F, Tuccinardi T. Application of MM-PBSA Methods in Virtual Screening. Mol Basel Switz 2020;25:1971. https://doi.org/10.3390/molecules25081971.
[40] https://github.com/dptech-corp/Uni-GBSA n.d.
[41] Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, et al. End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design. Chem Rev 2019;119:9478–508. https://doi.org/10.1021/acs.chemrev.9b00055.
[42] Seidel T, Schuetz DA, Garon A, Langer T. The Pharmacophore Concept and Its Applications in Computer-Aided Drug Design. Prog Chem Org Nat Prod 2019;110:99–141. https://doi.org/10.1007/978-3-030-14632-0_4.
[43] Amaro RE, Baudry J, Chodera J, Demir Ö, McCammon JA, Miao Y, et al. Ensemble Docking in Drug Discovery. Biophys J 2018;114:2271–8. https://doi.org/10.1016/j.bpj.2018.02.038.
[44] Mohammadi S, Narimani Z, Ashouri M, Firouzi R, Karimi‐Jafari MH. Ensemble learning from ensemble docking: revisiting the optimum ensemble size problem. Sci Rep 2022;12:410. https://doi.org/10.1038/s41598-021-04448-5.
[45] Blanes-Mira C, Fernández-Aguado P, de Andrés-López J, Fernández-Carvajal A, Ferrer-Montiel A, Fernández-Ballester G. Comprehensive Survey of Consensus Docking for High-Throughput Virtual Screening. Mol Basel Switz 2022;28:175. https://doi.org/10.3390/molecules28010175.
[46] Dos Santos Maia M, Soares Rodrigues GC, Silva Cavalcanti AB, Scotti L, Scotti MT. Consensus Analyses in Molecular Docking Studies Applied to Medicinal Chemistry. Mini Rev Med Chem 2020;20:1322–40. https://doi.org/10.2174/1389557520666200204121129.
[47] Liu X, Shi D, Zhou S, Liu H, Liu H, Yao X. Molecular dynamics simulations and novel drug discovery. Expert Opin Drug Discov 2018;13:23–37. https://doi.org/10.1080/17460441.2018.1403419.
[48] Wu X, Xu L-Y, Li E-M, Dong G. Application of molecular dynamics simulation in biomedicine. Chem Biol Drug Des 2022;99:789–800. https://doi.org/10.1111/cbdd.14038.
[49] Sasidharan S, Gosu V, Tripathi T, Saudagar P. Molecular Dynamics Simulation to Study Protein Conformation and Ligand Interaction. In: Saudagar P, Tripathi T, editors. Protein Fold. Dyn. Stab. Exp. Comput. Methods, Singapore: Springer Nature; 2023, p. 107–27. https://doi.org/10.1007/978-981-99-2079-2_6.
[50] Lage O, Ramos M, Calisto R, Almeida E, Vasconcelos V, Vicente F. Current Screening Methodologies in Drug Discovery for Selected Human Diseases. Mar Drugs 2018;16:279. https://doi.org/10.3390/md16080279.
[51] In Vitro Drug Testing - an overview | ScienceDirect Topics n.d. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/in-vitro-drug-testing (accessed June 29, 2023).
[52] Borhani DW, Shaw DE. The future of molecular dynamics simulations in drug discovery. J Comput Aided Mol Des 2012;26:15–26. https://doi.org/10.1007/s10822-011-9517-y.